FIV VAX

Development of a vaccine against Feline Immunodeficiency Virus

FIV VAX est accrédité par Lyonbiopôle

Identity card

Global budget: 4657 k€

Public funding: 1883 k€

Public funders: Conseil général de l'Isère, Conseil général de Rhône, Fonds Unique Interministériel (FUI) – DGCIS/Oséo, Grand Lyon

Call for projects: FUI (FUI AAP2)

Year start: 2006

Completed project (2010-12)


Accredited by the French competitiveness cluster Lyonbiopôle


Strategic business area: Animal Medicines

Application fields: Infectious diseases

Technological approaches / Keywords: Biologics, Cell model / Animal model, Innovative formulation, Vector vaccine

Stage of development at the beginning of the project: Discovery

Abstract

FIV VAX was the opportunity to test and compare in a standardized model several vaccine regimen based on recombinant FIV antigens (i.e. recombinant protein, viral vector, DNA). Vaccine efficacy required further development and analysis of the animal model (i.e. modelization of the virological and immunological parameters; development of new immunological techniques; FIV infection of the GAL; ...). In parallel, the study of infection in a metapopulation of cats led interesting results on the dynamics of infection and interaction with other parameters (i.e. other infections; hormonal status). 


Objectives

The goals of FIV VAX were : - To gather partners with expertise in the field of HIV and FIV, - To use FIV as a natural model of HIV to study further the early stage of infection and compare various vaccination strategies in a well-characterized model, - To use FIV and its host as a model to study the host-parasite interaction, in particular dynamics of transmission and interaction with other viruses, - To contribute to the development of new technology platforms for the production and formulation of antigens, or the identification of new molecules of interest for immunisation or diagnostic.


Innovative assets
Highlights
Actual results
Perspectives

Innovative assets

FIV VAX allowed Merial to reinforce its IP on DNA vaccine technology. It allowed the publication of several papers in internal peer-reviewed journals and presentations in international congresses or symposiums.

En poursuivant votre navigation sur notre site, vous acceptez l'utilisation des cookies et la collecte de vos données et informations personnelles par Lyonbiopôle, dans les finalités de mesurer le trafic sur le site Web, de fournir des statistiques et de vous proposer des contenus adaptés à vos centres d’intérets. Pour exercer vos droits d'accès, de rectification, d'opposition, de suppression et de portabilité, conformément au règlement général sur la protection des données (UE n°2016/679), vous etes informés que vous pouvez envoyer votre demande à dpo@lyonbiopole.com. Plus de détails sont disponibles en cliquant ici J'accepte